Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs RCUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–3 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: CAPR 3 – 2 RCUS (1 Tie) Matrix Metrics: CAPR 6 – 3 RCUS

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas RCUS carries 48.7/100 (HOLD) at $16.97 (N/M Forward P/E, -475.0% operating margin).

  • Composite vs. Pillar Nuance: While RCUS currently prints a higher short-term Unified Composite Score (48.7/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -475.0% operating margin) and revenue trajectory (-7.9% vs. -65.4% YoY).
  • Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs RCUS
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
RCUS NYSE
Arcus Biosciences, Inc.
Pharmaceutical Preparations
$16.97
-2.64% 1D
Market Cap $2.6B
TTM Revenue $100M
Forward P/E N/M
Beta / 30D Vol 1.56β · 90% Vol
Unified Composite Score
48.7 / 100 HOLD
Tech 49.0 Fund 59.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 34
RSI-14: 33.6 · SMA20: $18.63 · SMA50: $22.37

6-Pillar Scorecard Institutional Category Breakdown (CAPR 3 – 2 RCUS)

Columns: Metric · CAPR · RCUS
1. Valuation Multiples CAPR
Forward P/E 78.7x N/M
Trailing P/E 78.7x N/M
PEG Ratio 0.38x N/M
EV / Revenue 57.8x 25.2x
2. Growth & Scale RCUS
Revenue Growth (YoY) -7.9% -65.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $100M
Market Cap $595.4M $2.6B
3. Profitability & Quality CAPR
Gross Margin N/A N/A
Operating Margin 0.0% -475.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -100.5% -114.1%
4. Balance Sheet & Cash Flow RCUS
Cash Generation (TTM) -$146M -$466M
Cash Flow Margin N/A N/A
Net Cash / Leverage $48M Net Debt (0.44x D/E) $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 637.1% (89th %ile) 43.1% (1st %ile)
Put/Call OI Skew 1.57x (Put-Skewed) 0.08x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (6) vs RCUS (3)
Institutional Metric CAPR RCUS Criterion Row Edge
Market Capitalization
Scale
$595.4M $2.6B Larger Scale RCUS
Trailing P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Forward P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Revenue Growth (YoY)
Growth
-7.9% -65.4% Higher Growth CAPR
Operating Margin (TTM)
Profitability
0.0% -475.0% Higher Margin CAPR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-100.5% -114.1% Higher ROE CAPR
52-Week Range Position
Momentum
15% ($3–$40) 1% ($17–$32) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 1.56β · 90% Vol Lower Realized Risk RCUS
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 48.7 / 100 (HOLD) Higher Composite RCUS
Trailing 12M Revenue (USD)
Operating Scale
$11M $100M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev N/M PEG · 25.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) -$466M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +49.51 pp
CAPR: +26.23% · RCUS: -23.28%
3M Horizon CAPR +62.12 pp
CAPR: +19.63% · RCUS: -42.49%
6M Horizon RCUS +41.94 pp
CAPR: -70.58% · RCUS: -28.64%
1Y Horizon CAPR +61.04 pp
CAPR: +46.79% · RCUS: -14.25%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAPR Revenue RCUS Revenue CAPR Op. Margin RCUS Op. Margin Margin Leader
FY2018 $0M $10M -917.0% -656.8% RCUS
FY2019 $0M $10M -769.5% -591.4% RCUS
FY2020 $0M $80M -4412.6% -159.0% RCUS
FY2021 $0M $380M -8549.9% 14.1% RCUS
FY2022 $0M $40M -1163.9% -736.8% RCUS
FY2023 $30M $40M -95.6% -918.9% CAPR
FY2024 $20M $50M -191.1% -647.1% CAPR
FY2025 N/A $30M N/A -1169.7% RCUS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCUS BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 43.1%
IV Percentile 1st %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RCUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RCUS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.6B market capitalization and -475.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs RCUS Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas RCUS carries 48.7/100 (HOLD) at $16.97 (N/M Forward P/E, -475.0% operating margin). Composite vs. Pillar Nuance: While RCUS currently prints a higher short-term Unified Composite Score (48.7/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -475.0% operating margin) and revenue trajectory (-7.9% vs. -65.4% YoY). Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCUS leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with RCUS at -65.4% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (N/A gross margin, -475.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CAPR cumulative revenue shifted -33.3% while RCUS shifted +200.0%. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCUS.

CAPR screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas RCUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 25.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus RCUS (-114.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, RCUS carries 43.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.